[1]
J. D’antuoni, “Is it possible to reduce the dose of tyrosine kinase inhibitors and maintain response in chronic-phase Philadelphia chromosome– positive chronic myeloid leukemia? A single-center experience”., RH, vol. 30, no. 1, pp. 63–71, May 2026.